Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Articles
Articles
Ribociclib Plus Endocrine Therapy Found to Improve Progression-Free Survival and Overall Survival in Elderly Patients
SABCS 2023 HR+/HER2- MBC
Pooled analysis of the MONALEESA-2, -3, and -7 clinical trials finds elderly patients have survival benefits from treatment with ribociclib plus endocrine therapy.
Read More ›
Clinical Meaningfulness Poorly Understood and Often Not Considered in the Metastatic Breast Cancer Clinical Setting
SABCS 2023 HR+/HER2- MBC
Focus group analysis of stakeholders in metastatic breast cancer treatment finds a need for accessible and patient-friendly terminology in metastatic breast cancer treatment-making discussions.
Read More ›
CDK4/6 Inhibitors Plus Radiotherapy for Patients With HR+/HER2– Advanced Breast Cancer With Brain Metastases
SABCS 2023 HR+/HER2- MBC
The use of CDK4/6 inhibitors following radiotherapy demonstrated to be safe and effective in patients with HR+/HER2– advanced breast cancer who develop brain metastases.
Read More ›
First-Line Treatment Sequencing Associated With an Improved Progression-Free Survival in Patients With Metastatic Breast Cancer
SABCS 2023 HR+/HER2- MBC
Recent retrospective study finds that receiving CDK4/6 inhibitor plus endocrine therapy improves progression-free survival in patients with HR+/HER2– metastatic breast cancer.
Read More ›
DLL3-Targeting T-Cell Engager HPN328 Shows Clinical Activity in SCLC and NEN
ESMO 2023 - Small Cell Lung Cancer
Interim results from a phase 1/2 study that evaluated the clinical safety and efficacy of HPN328, a trispecific, delta-like canonical Notch ligand 3 (DLL3)–targeting T-cell engager, in patients with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NENs) was presented at the 2023 ESMO annual meeting.
Read More ›
Induction Therapy With PD-L1 Inhibitor TQB2450 + Chemotherapy Followed by Surgery or Radiotherapy in Limited-Stage SCLC
ESMO 2023 - Small Cell Lung Cancer
Based on improvements in survival outcomes with a PD-1/PD-L1 inhibitor in combination with chemotherapy in patients with extensive-stage small cell lung cancer (SCLC), a nonrandomized, single-center, phase 2 study (LungMate-005; NCT04539977) was conducted to explore the clinical safety and efficacy of neoadjuvant PD-L1 inhibitor TQB2450 plus chemotherapy induction therapy followed by surgery or radiotherapy in patients with limited-stage small-cell lung cancer (LS-SCLC).
Read More ›
CANTABRICO Trial: Safety Profile of First-Line Durvalumab Plus Platinum/Etoposide in Extensive-Stage SCLC
ESMO 2023 - Small Cell Lung Cancer
The majority of patients with small cell lung cancer (SCLC) present with extensive-stage disease, which is associated with poor prognosis.
Read More ›
Real-World Data From the IMreal Trial (Cohort 4) of First-Line Atezolizumab Plus Carboplatin/Etoposide in Patients With Extensive-Stage SCLC
ESMO 2023 - Small Cell Lung Cancer
Atezolizumab plus carboplatin/etoposide is indicated for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) based on results of the pivotal phase 3 IMpower133 trial.
Read More ›
LUPER Study Results: Lurbinectedin + Pembrolizumab in Relapsed SCLC
ESMO 2023 - Small Cell Lung Cancer
Phase 1 results of the prospective, open-label, uncontrolled, multicenter, phase 1/2 LUPER study (NCT04358237) indicated that the lurbinectedin plus the anti–PD-1 pembrolizumab combination regimen showed promising antitumor activity with a manageable safety profile in patients with relapsed small cell lung cancer (SCLC) and established the recommended phase 2 dose (RP2D) of lurbinectedin + pembrolizumab.
Read More ›
TROPiCS-03 Basket Trial Results of Second-Line Sacituzumab Govitecan for Extensive-Stage SCLC
ESMO 2023 - Small Cell Lung Cancer
Extensive-stage small cell lung cancer (ES-SCLC) is often treated with a combination of immunotherapy and chemotherapy; however, limited treatment options are available following progression on this combination regimen, underscoring the need for novel therapies in the second-line setting.
Read More ›
Page 5 of 136
2
3
4
5
6
7
8
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us